Trials / Unknown
UnknownNCT04236362
A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
A Phase Ib, Single Arm, Open-label Study of TQB2450 Combined With Anlotinib in Subjects With Relapsed / Refractory Gynecological Cancer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, phase Ib clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib in subjects with gynecological cancer, including 34 ovarian cancer，34 endometrial cancer，22 cervical cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2450 | TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. |
| DRUG | Anlotinib | A multi-target receptor tyrosine kinase inhibitor |
Timeline
- Start date
- 2020-02-27
- Primary completion
- 2021-12-31
- Completion
- 2022-05-30
- First posted
- 2020-01-22
- Last updated
- 2021-01-12
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04236362. Inclusion in this directory is not an endorsement.